Literature DB >> 36267136

Novel Lactams as Cbl-b Inhibitors for Treating Cancer.

Ram W Sabnis1.   

Abstract

Provided herein are novel lactams as Cbl-b inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds. Published 2022 by American Chemical Society.

Entities:  

Year:  2022        PMID： 36267136      PMCID： PMC9578024          DOI： 10.1021/acsmedchemlett.2c00413

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


  3 in total

Review 1.  Ubiquitin ligase Cbl-b and inhibitory Cblin peptides.

Authors:  Takeshi Nikawa; Kazumi Ishidoh
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-07-12       Impact factor: 3.036

Review 2.  Regulation of immune responses by E3 ubiquitin ligase Cbl-b.

Authors:  Rong Tang; Wallace Y Langdon; Jian Zhang
Journal:  Cell Immunol       Date:  2018-11-07       Impact factor: 4.868

Review 3.  K63 ubiquitination in immune signaling.

Authors:  Charitha Madiraju; Jeffrey P Novack; John C Reed; Shu-Ichi Matsuzawa
Journal:  Trends Immunol       Date:  2022-01-13       Impact factor: 16.687
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.